European Association for the Study of the Liver

Last updated

European Association for the Study of the Liver
Company type Non-profit organisation
Founded1966
HeadquartersGeneva, Switzerland
Members3589 (April 2014)
Website EASL

The European Association for the Study of the Liver (EASL), founded in 1966, is a medical association dedicated to pursuing excellence in liver research, to the clinical practice of liver disorders, and to providing education to all those interested in hepatology. As of 2024, EASL serves 7,000 members from 112 countries.[ citation needed ]

Contents

History

EASL was founded by the German physician Gustav-Adolf Martini [1] in April 1966, in Marburg, Germany, to promote research on the liver and its pathology and to improve therapy for liver disorders. [2] EASL's founding was inspired by the American Association for the Study of Liver Diseases (AASLD, created in November 1949) and the International Association for the Study of the Liver (IASL, created in 1958). [1]

Structure

EASL is a nonprofit organization, composed solely of individual members, that performs its duties under a written constitution managed by the EASL Governing Board made up of 11 elected members: the Secretary General, the Vice-Secretary, the Scientific Committee (five persons), the Treasurer, the Educational Councillors (two persons), and the European Policy Councillor. [3] EASL is an Ordinary Member of the United European Gastroenterology.

EASL members meet several times per year and have the annual general meeting during the International Liver Congress. [4]

International Liver Congress

EASL organizes the International Liver Congress, held in various European cities, usually in April. [4] This is an annual scientific meeting where experts and researchers receive information on the latest research, perspectives and treatments of liver disease. Medical experts and specialists will share recent data, present studies and findings, and discuss topics on liver disease. The International Liver Congress attracts more than 9,000 delegates from all over the world. [5]

Journal of Hepatology

The Journal of Hepatology is a monthly, English language, peer-reviewed journal, edited by EASL and published by Elsevier. [6] As the official journal of EASL, it provides an international forum for the publication of original articles, reviews and letters to the Editor describing basic laboratory, translational, and clinical investigations in hepatology. All articles undergo a rigorous peer review and are selected based on the originality of the findings, the superior quality of the work described, and the clarity of presentation. In 2021, the Journal of Hepatology had an impact factor of 30.083. [7]

The Journal of Hepatology also publishes EASL's Clinical Practice Guidelines. [8] These guidelines assist physicians, healthcare providers, patients and other interested parties in the clinical decision-making process. The EASL Guidelines present a range of state-of-the-art approaches for the diagnosis and treatment of liver diseases. [9] [10] [11] [12] [13]

See also

Related Research Articles

<span class="mw-page-title-main">Hepatitis</span> Inflammation of the liver

Hepatitis is inflammation of the liver tissue. Some people or animals with hepatitis have no symptoms, whereas others develop yellow discoloration of the skin and whites of the eyes (jaundice), poor appetite, vomiting, tiredness, abdominal pain, and diarrhea. Hepatitis is acute if it resolves within six months, and chronic if it lasts longer than six months. Acute hepatitis can resolve on its own, progress to chronic hepatitis, or (rarely) result in acute liver failure. Chronic hepatitis may progress to scarring of the liver (cirrhosis), liver failure, and liver cancer.

<span class="mw-page-title-main">Alcoholic hepatitis</span> Medical condition

Alcoholic hepatitis is hepatitis due to excessive intake of alcohol. Patients typically have a history of at least 10 years of heavy alcohol intake, typically 8–10 drinks per day. It is usually found in association with fatty liver, an early stage of alcoholic liver disease, and may contribute to the progression of fibrosis, leading to cirrhosis. Symptoms may present acutely after a large amount of alcoholic intake in a short time period, or after years of excess alcohol intake. Signs and symptoms of alcoholic hepatitis include jaundice, ascites, fatigue and hepatic encephalopathy. Mild cases are self-limiting, but severe cases have a high risk of death. Severity in alcoholic hepatitis is determined several clinical prediction models such as the Maddrey's Discriminant Function and the MELD score.

<span class="mw-page-title-main">Autoimmune hepatitis</span> Chronic, autoimmune disease of the liver

Autoimmune hepatitis, formerly known as lupoid hepatitis, plasma cell hepatitis, or autoimmune chronic active hepatitis, is a chronic, autoimmune disease of the liver that occurs when the body's immune system attacks liver cells, causing the liver to be inflamed. Common initial symptoms may include fatigue, nausea, muscle aches, or weight loss or signs of acute liver inflammation including fever, jaundice, and right upper quadrant abdominal pain. Individuals with autoimmune hepatitis often have no initial symptoms and the disease may be detected by abnormal liver function tests and increased protein levels during routine bloodwork or the observation of an abnormal-looking liver during abdominal surgery.

<span class="mw-page-title-main">Primary biliary cholangitis</span> Autoimmune disease of the liver

Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver. It results from a slow, progressive destruction of the small bile ducts of the liver, causing bile and other toxins to build up in the liver, a condition called cholestasis. Further slow damage to the liver tissue can lead to scarring, fibrosis, and eventually cirrhosis.

<span class="mw-page-title-main">Primary sclerosing cholangitis</span> Hardening of the bile ducts due to scarring and inflammation

Primary sclerosing cholangitis (PSC) is a long-term progressive disease of the liver and gallbladder characterized by inflammation and scarring of the bile ducts, which normally allow bile to drain from the gallbladder. Affected individuals may have no symptoms or may experience signs and symptoms of liver disease, such as yellow discoloration of the skin and eyes, itching, and abdominal pain.

<span class="mw-page-title-main">Roger Williams (hepatologist)</span> British hepatologist (1931–2020)

Roger Stanley Williams CBE FRCS FRCP FRCPE FRACP FMedSci was a British professor of hepatology. He was Director of the Institute of Hepatology, London and Professor of Hepatology, King's College London. He was also Medical Director of the charity, the Foundation for Liver Research a UK registered charity and was the lead person of the Lancet Commission into Liver Disease in the UK.

<span class="mw-page-title-main">Metabolic dysfunction–associated steatotic liver disease</span> Excessive fat buildup in the liver with other metabolic disease

Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is a type of chronic liver disease. This condition is diagnosed when there is excessive fat build-up in the liver, and at least one metabolic risk factor. When there is also increased alcohol intake, the term MetALD, or metabolic dysfunction and alcohol associated/related liver disease is used, and differentiated from alcohol-related liver disease (ALD) where alcohol is the predominant cause of the steatotic liver disease. The terms non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis have been used to describe different severities, the latter indicating the presence of further liver inflammation. NAFL is less dangerous than NASH and usually does not progress to it, but this progression may eventually lead to complications, such as cirrhosis, liver cancer, liver failure, and cardiovascular disease.

<span class="mw-page-title-main">Hashem El-Serag</span> Palestinian-American physician

Hashem B. El-Serag is a Palestinian-American physician and medical researcher best known for his research in liver cancer, hepatocellular carcinoma (HCC) and the hepatitis C virus. He serves as the Margaret M. and Albert B. Alkek Chairman of the Department of Medicine at Baylor College of Medicine as well as the co-director of the Texas Medical Center Digestive Disease Center. El-Serag previously served as president of the American Gastroenterological Association and Editor-in-Chief of Clinical Gastroenterology and Hepatology.

<span class="mw-page-title-main">Cirrhosis</span> Chronic disease of the liver, characterized by fibrosis

Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis, and end-stage liver disease, is a condition of the liver in which the normal functioning tissue, or parenchyma, is replaced with scar tissue (fibrosis) and regenerative nodules as a result of chronic liver disease. Damage to the liver leads to repair of liver tissue and subsequent formation of scar tissue. Over time, scar tissue and nodules of regenerating hepatocytes can replace the parenchyma, causing increased resistance to blood flow in the liver's capillaries—the hepatic sinusoids—and consequently portal hypertension, as well as impairment in other aspects of liver function. The disease typically develops slowly over months or years.

Elizabeth Jane "Jenny" Heathcote was a professor of medicine at the University of Toronto and a gastroenterologist and scientist at University Health Network in Toronto specializing in liver disease. She retired in 2013.

<span class="mw-page-title-main">Andrew Kenneth Burroughs</span> British physician, researcher and teacher

Andrew K. Burroughs was a British physician, researcher and teacher. He is renowned for his wide contribution to the field of Hepatology; he has been termed one of the greatest hepatologists of our times and the true representative of Dame Sheila Sherlock's legacy.

Clodoveo Ferri is an Italian researcher of clinical rheumatology, immunology and internal medicine. Since January 2003, Clodoveo Ferri has been a professor of rheumatology, Chief of the Chair of Rheumatology and director of the Postgraduate School of Rheumatology at the University of Modena and Reggio Emilia in Modena, Italy. A native of Cropani, a small town in Calabria, Italy, Clodoveo Ferri graduated cum laude from the University of Pisa and later specialized in internal medicine and rheumatology.

Detlef Schuppan is a German biochemist and physician. He focuses on the diagnosis and treatment of coeliac disease and wheat sensitivity, fibrotic liver diseases and the immunology of chronic diseases and cancer. He is the director of the Institute of Translational Immunology and a professor of internal medicine, gastroenterology, and hepatology at the Medical Center of the Johannes Gutenberg University of Mainz in Germany. He directs the outpatient clinic for coeliac disease and small intestinal diseases. He is also a professor of medicine and a senior visiting scientist at Harvard Medical School.

<span class="mw-page-title-main">Gamal Esmat</span>

Gamal Esmat is a professor at Endemic Medicine and Hepatogastroenterology Department, Cairo University. He was vice president of Cairo University for Graduate Studies and Research.

Anna Suk-Fong Lok is a gastroenterologist who studied in Hong Kong and moved to the United States in 1992. She is a Professor of Medicine at the University of Michigan in Ann Arbor and helped the World Health Organization (WHO) and American Association for the Study of Liver Diseases (AASLD) develop guidelines for medical professionals and recommendations for the general public on who should be treated and how treatments should be administered to persons with hepatitis B infections.

Shiv Kumar Sarin is an Indian gastroenterologist, hepatologist, translational scientist, researcher and teacher. He set up the Institute of Liver and Biliary Sciences. He is a recipient of the Shanti Swarup Bhatnagar Prize and the Padma Bhushan. He served as chairman of the Board of Governors of Medical Council of India. He was the president of the Asian Pacific Association for the Study of the Liver and founder of Asian Pacific School of Hepatology.

<span class="mw-page-title-main">Ding-Shinn Chen</span> Taiwanese physician and hepatologist (1943–2020)

Ding-Shinn Chen was a Taiwanese hepatologist.

<span class="mw-page-title-main">Mamun Al Mahtab</span> Bangladeshi hepatologist

Mamun Al Mahtab is a Bangladeshi doctor, hepatologist, medical scientist, and author. With 290 publications in national and international peer-reviewed journals to his credit, Mahtab works as the Head, Division of Interventional Hepatology, Bangabandhu Sheikh Mujib Medical University (BSMMU).He has some scandals about wrong treatment.Some case are running still three years. Also did same mistake in 2023 and february 2024. Most pathetic mistake he did with a young doctor who died for professor's wrong treatment.

<span class="mw-page-title-main">Jesús Prieto</span> Spanish medical doctor and scientist

Jesus M. Prieto is a Spanish medical doctor and scientist who is at present Emeritus Professor of Medicine at the University of Navarra.

<span class="mw-page-title-main">European Liver Patients' Association</span> European NGO for liver patients

The European Liver Patients' Association (ELPA) is an international non-governmental organisation best known for its role in patient advocacy concerning liver diseases. ELPA is an umbrella organisation representing more than 30 members stemming from 25 European and non-European countries.

References

  1. 1 2 Martini, G.A. (1991). "Foundation and Development of the EASL". Journal of Hepatology. 13 (2): 135–136. doi:10.1016/0168-8278(91)90804-K.
  2. "Liver disease research announced at disease-specific conference". Drug Week. 20 May 2005. p. 537. Retrieved 5 May 2011 via NewsRx.com.
  3. "Governing Board". EASL.
  4. 1 2 "Experience The Digital International Liver Congress™, 27-29 August 2020". Digital International Liver Congress 2020. Retrieved 1 June 2020.
  5. "EASL 2024 - European Association for the Study of the Liver". annual2024summit.com.
  6. "Home Page: Journal of Hepatology". journal-of-hepatology.eu.
  7. "Journal of Hepatology" . Retrieved 14 October 2020.
  8. "EASL Clinical Practice Guidelines". EASL-The Home of Hepatology.
  9. "Treatment of Hepatitis C – 2018 EASL Recommendations". EASL-The Home of Hepatology.
  10. "Management of Decompensated Cirrhosis EASL Guideline". EASL-The Home of Hepatology.
  11. "Hepatitis B EASL Guidelines". EASL-The Home of Hepatology.
  12. "Hepatocellular Carcinoma EASL Guideline". EASL-The Home of Hepatology.
  13. "Management of Alcohol-Related Liver Disease". EASL-The Home of Hepatology.